Five stages of evolving beta-cell dysfunction during progression to diabetes
- PMID: 15561905
- DOI: 10.2337/diabetes.53.suppl_3.s16
Five stages of evolving beta-cell dysfunction during progression to diabetes
Abstract
This article proposes five stages in the progression of diabetes, each of which is characterized by different changes in beta-cell mass, phenotype, and function. Stage 1 is compensation: insulin secretion increases to maintain normoglycemia in the face of insulin resistance and/or decreasing beta-cell mass. This stage is characterized by maintenance of differentiated function with intact acute glucose-stimulated insulin secretion (GSIS). Stage 2 occurs when glucose levels start to rise, reaching approximately 5.0-6.5 mmol/l; this is a stable state of beta-cell adaptation with loss of beta-cell mass and disruption of function as evidenced by diminished GSIS and beta-cell dedifferentiation. Stage 3 is a transient unstable period of early decompensation in which glucose levels rise relatively rapidly to the frank diabetes of stage 4, which is characterized as stable decompensation with more severe beta-cell dedifferentiation. Finally, stage 5 is characterized by severe decompensation representing a profound reduction in beta-cell mass with progression to ketosis. Movement across stages 1-4 can be in either direction. For example, individuals with treated type 2 diabetes can move from stage 4 to stage 1 or stage 2. For type 1 diabetes, as remission develops, progression from stage 4 to stage 2 is typically found. Delineation of these stages provides insight into the pathophysiology of both progression and remission of diabetes.
Similar articles
-
Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance.Diabetes. 2004 Mar;53(3):645-53. doi: 10.2337/diabetes.53.3.645. Diabetes. 2004. PMID: 14988248
-
Beta-cell adaptation and decompensation during the progression of diabetes.Diabetes. 2001 Feb;50 Suppl 1:S154-9. doi: 10.2337/diabetes.50.2007.s154. Diabetes. 2001. PMID: 11272180 Review.
-
Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.Diabetes. 2000 Mar;49(3):399-408. doi: 10.2337/diabetes.49.3.399. Diabetes. 2000. PMID: 10868961
-
The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus.Am J Med. 2000 Apr 17;108 Suppl 6a:2S-8S. doi: 10.1016/s0002-9343(00)00336-3. Am J Med. 2000. PMID: 10764844 Review.
-
Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat.Diabetes. 1995 Dec;44(12):1447-57. doi: 10.2337/diab.44.12.1447. Diabetes. 1995. PMID: 7589853
Cited by
-
Effect of transgenerational diabetes via maternal lineage in female rats.Heliyon. 2024 May 10;10(10):e31049. doi: 10.1016/j.heliyon.2024.e31049. eCollection 2024 May 30. Heliyon. 2024. PMID: 38803977 Free PMC article.
-
Predictors of glycemic worsening in the next year in adults with screen-detected type 2 diabetes.medRxiv [Preprint]. 2024 Apr 27:2024.04.25.24306391. doi: 10.1101/2024.04.25.24306391. medRxiv. 2024. PMID: 38712131 Free PMC article. Preprint.
-
Galectin-3 impairs calcium transients and β-cell function.Nat Commun. 2024 May 1;15(1):3682. doi: 10.1038/s41467-024-47959-1. Nat Commun. 2024. PMID: 38693121 Free PMC article.
-
Diabetic Rats Induced Using a High-Fat Diet and Low-Dose Streptozotocin Treatment Exhibit Gut Microbiota Dysbiosis and Osteoporotic Bone Pathologies.Nutrients. 2024 Apr 19;16(8):1220. doi: 10.3390/nu16081220. Nutrients. 2024. PMID: 38674910 Free PMC article.
-
Effect of chitooligosaccharides with a specific degree of polymerization on multiple targets in T2DM mice.Bioresour Bioprocess. 2022 Sep 5;9(1):94. doi: 10.1186/s40643-022-00579-3. Bioresour Bioprocess. 2022. PMID: 38647883 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical